[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556500":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":28,"responsibleParty":92,"collaborators":10,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":10,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":102,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":10,"studyType":108,"phases":10,"briefSummary":109,"conditions":110,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Untreated group",null,"The untreated patients who met the staging subgroups of the Chinese Guidelines for the Prevention and Control of Chronic Hepatitis B, 2022 edition or lost HBsAg spontaneously.",{"label":13,"type":10,"description":14,"interventionNames":10},"NA treatment group","The patients who achieved HBV DNA suppression by NA.",[16],{"name":17,"affiliation":18,"role":19},"Qin Ning, Doctor","Department of infectious Diseases, Tongji Hospital","PRINCIPAL_INVESTIGATOR",[21,25],{"name":17,"role":22,"phone":23,"phoneExt":10,"email":24},"CONTACT","862783662391","qning@vip.sina.com",{"name":26,"role":22,"phone":23,"phoneExt":10,"email":27},"Meifang Han, Doctor","mfan@foxmail.com",[29,47,58,70,81],{"facility":5,"status":30,"city":31,"state":32,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Wuhan","Hubei","China","CN",{"type":36,"coordinates":37},"Point",[38,39],114.26667,30.58333,{"lat":39,"lon":38},[42,44],{"name":17,"role":22,"phone":43,"phoneExt":10,"email":24},"02783662391",{"name":45,"role":22,"phone":43,"phoneExt":10,"email":46},"Meifang Han","mfhan@foxmail.com",{"facility":48,"status":30,"city":49,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"Beijing YouAn Hospital","Beijing",{"type":36,"coordinates":51},[52,53],116.39723,39.9075,{"lat":53,"lon":52},[56],{"name":57,"role":22,"phone":10,"phoneExt":10,"email":10},"Wei Hou",{"facility":59,"status":60,"city":61,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"The First Hospital of Jilin University","NOT_YET_RECRUITING","Changchun",{"type":36,"coordinates":63},[64,65],125.32278,43.88,{"lat":65,"lon":64},[68],{"name":69,"role":22,"phone":10,"phoneExt":10,"email":10},"Junqi Niu",{"facility":71,"status":60,"city":72,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Southwest Hospital","Chongqing",{"type":36,"coordinates":74},[75,76],106.55771,29.56026,{"lat":76,"lon":75},[79],{"name":80,"role":22,"phone":10,"phoneExt":10,"email":10},"Qing Mao",{"facility":82,"status":60,"city":83,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Jiangsu Province Hospital","Nanjing",{"type":36,"coordinates":85},[86,87],118.77778,32.06167,{"lat":87,"lon":86},[90],{"name":91,"role":22,"phone":10,"phoneExt":10,"email":10},"Chuanlong Zhu",{"type":19,"investigatorFullName":93,"investigatorTitle":94,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Qin Ning","Director and Chair of Department of Infectious Diseases","100556500","a-real-world-study-of-staging-and-grading-of-clinical-immune-status-in-chronic-hepatitis-b-100556500",false,"NCT06525909","A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B","Inclusion Criteria:\n\n1. Patients with CHB who were older than 18 years old and younger than 50 years old with HBsAg positivity more than 6 months;\n2. Group 1 untreated group fulfils any one of the four natural history types of the Chinese Guidelines for the Prevention and Control of Chronic Hepatitis B, 2022.\n3. Group 2 nucleos(t)ide-treated CHB patients are required to have sustained control of their HBV DNA (\\\u003C100 IU\u002Fml).\n\nExclusion Criteria:\n\n1. Pregnancy status;\n2. Has been diagnosed with compensated\u002Flost compensated cirrhosis, hepatocellular carcinoma by imaging or other indicators;\n3. Combined HAV, HCV, HEV infection, schistosomal liver disease, drug-induced liver injury, autoimmune hepatitis, alcoholic liver disease, severe fatty liver, HIV infection;\n4. Being on immunosuppressants or immunomodulators or hormonal drugs or biological agents, etc;\n5. previous history of oncology, organ transplantation, etc., history of alcoholism (\\>30 g\u002Fd for men, \\>20 g\u002Fd for women);\n6. Inadequate follow-up time and inadequate clinical\u002Flaboratory information;\n7. Combined heart, brain, kidney, lung and other organ insufficiency or combined endocrine and haematological system and other major diseases;\n8. Comorbid serious psychiatric diseases including severe anxiety or depression;\n9. Unwilling to participate in this study.",true,"ALL","18 Years","50 Years",{"count":106,"type":107},250,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicentre observational study of Chronic Hepatitis B （CHB）in different clinical stages. We intend to compare the immune status of various types of CHB patients, and we propose to establish a staging and grading criteria for the immune exhaustion status of patients with CHB.",[111],"Hepatitis B, Chronic","2024-07-24",{"date":114,"type":115},"2024-07-29","ACTUAL",{"date":117,"type":115},"2024-01-20",{"date":119,"type":107},"2028-12-10",{"name":5,"class":6},5]